Indomethacin improves locomotor deficit and reduces brain concentrations of neuroinhibitory steroids in rats following portacaval anastomosis.
Hepatic encephalopathy (HE) is a neuropsychiatric complication of both acute and chronic liver failure characterized by progressive neuronal inhibition. Some neurosteroids are potent positive allosteric modulators of the gamma-aminobutyric acid (GABA)-A receptor complex, and 'increased GABAergic tone' has been proposed to explain the neuroinhibition characteristics of HE. Brain levels of the neurosteroids pregnenolone, allopregnanolone and tetrahydrodesoxycorticosterone (THDOC) and the functional status of the GABA-A receptor complex were assessed in rats following portacaval anastomosis (PCA). Effects of indomethacin, an inhibitor of the 3alpha-hydroxysteroid dehydrogenase enzyme involved in neurosteroid synthesis, on PCA rat locomotor activity and brain neurosteroid levels were also assessed. Significant increases of the neurosteroid pregnenolone (2.6-fold), allopregnanolone (1.7-fold) and THDOC (4.7-fold) were observed in brains of PCA rats. Brain levels of these neurosteroids were in the nanomolar range, sufficient to exert positive allosteric modulatory effects at the GABA-A receptor. Indomethacin (0.1-5 mg kg(-1)) ameliorated dose-dependently the locomotor deficit of PCA rats and concomitantly normalized brain levels of allopregnanolone and THDOC. Increased brain levels of neurosteroids with positive allosteric modulatory actions at the neuronal GABA-A receptor offer a cogent explanation for the notion of 'increased GABAergic tone' in HE. Pharmacological approaches using agents that either reduce neurosteroid synthesis or modulate the neurosteroid site on GABA-A receptor could offer new therapeutic tools for the management and treatment of HE.
Ahboucha
S
S
Neuroscience Research Unit, Université de Montréal, CHUM (Hôpital Saint-Luc), Montreal, QC, Canada. samir.ahboucha@ualberta.ca
Jiang
W
W
Chatauret
N
N
Mamer
O
O
Baker
G B
GB
Butterworth
R F
RF
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D001259:Ataxia / Q000503:physiopathology*; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D001923:Brain Chemistry; D003900:Desoxycorticosterone / Q000031:analogs & derivatives / Q000737:chemistry / Q000378:metabolism; D006501:Hepatic Encephalopathy / Q000503:physiopathology; D006801:Humans; D007213:Indomethacin / Q000494:pharmacology*; D008297:Male; D015394:Molecular Structure; D009043:Motor Activity / Q000187:drug effects*; D011167:Portacaval Shunt, Surgical; D011280:Pregnanolone / Q000737:chemistry / Q000378:metabolism; D011284:Pregnenolone / Q000737:chemistry / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D011963:Receptors, GABA-A / Q000378:metabolism; D013256:Steroids / Q000737:chemistry / Q000378:metabolism*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D011963:Receptors, GABA-A; D013256:Steroids; D003900:Desoxycorticosterone; C009413:tetrahydrodeoxycorticosterone; D011284:Pregnenolone; D011280:Pregnanolone; D007213:Indomethacin